Methotrexate, Erlotinib, and Celecoxib for the Treatment of Recurrent/Metastatic Oral Cavity Cancer in a Rural Midwest United States Population
Mayo Clinic
Mayo Clinic
M.D. Anderson Cancer Center
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Montefiore Medical Center
National Cancer Institute (NCI)
UNC Lineberger Comprehensive Cancer Center
Canadian Cancer Trials Group
National Cancer Institute (NCI)
Genentech, Inc.
Eli Lilly and Company
Eli Lilly and Company
Boundless Bio, Inc.
Eli Lilly and Company
Exelixis
St. Jude Children's Research Hospital
AstraZeneca
Precision Biotech Taiwan Corp.
National Cancer Institute (NCI)
M.D. Anderson Cancer Center
NRG Oncology
University of Texas Southwestern Medical Center
Hoffmann-La Roche
Astellas Pharma Inc
Astellas Pharma Inc
AstraZeneca
Massachusetts General Hospital
Centre Antoine Lacassagne
Alpha Biopharma (Jiangsu) Co., Ltd.
M.D. Anderson Cancer Center
AbbVie
OBI Pharma, Inc
Rigshospitalet, Denmark
National Institutes of Health Clinical Center (CC)
Io Therapeutics
Thomas Jefferson University
Thomas Jefferson University
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Thomas Jefferson University